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Abstract
Background: We have previously reported that unilateral groin-single transseptal
(ST) ablation in patients with paroxysmal atrial fibrillation (AF) was safe and signifi-
cantly reduced patient discomfort compared with bilateral groin-double transseptal
(DT) ablation.
Hypothesis: In the present study, we hypothesized that ST ablation would be as
effective and safe as DT ablation in real-world practice like previous study. Among
the 1765 consecutive patients in the Yonsei AF ablation cohort from October 2015
to January 2020, 1144 patients who underwent radiofrequency ablation
were included for the analysis. Among them, 450 underwent ST ablation and
694 underwent DT ablation.
Results: The total procedure time, ablation time, and fluoroscopy time were longer in
the ST group than in the DT group (p < .05 for all). The hospital stay after catheter
ablation was 1.3 ± 1.1 days which was longer in DT group than ST group (p = .001).
No significant difference was observed in the complication rate (p = .263) and AF-
free survival rate (log-rank p = .19) between the groups. However, after excluding
patients who used antiarrhythmic drugs when AF recurred, the AF-free survival rates
were lower in the DT group than in the ST group before and after propensity score
matching (log-rank p = .026 and .047, respectively).
Conclusion: Although the ST approach increases the procedure time compared with
the DT approach owing to the need for more frequent catheter exchanges, the ST
approach is a feasible and safe strategy for AF ablation in terms of rhythm outcomes
and risk of complications.
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1 | INTRODUCTION
Catheter ablation is effective in rhythm control of atrial fibrillation
(AF) and maintaining sinus rhythm.1-5 After a study identified triggers
of paroxysmal AF in the pulmonary veins (PVs), catheter ablation of
AF has become a more common treatment method.6,7 Complete PV
isolation is a well-proven endpoint for catheter ablation by encircling
the PVs.8,9 To approach the PVs via the left atrium (LA) during AF
ablation, transseptal puncture is performed.10 Although some compli-
cations have been reported, such as cardiac tamponade, stroke, and
persistence of the septal defect after transseptal puncture,11-13
several reports have shown the safety of transseptal puncture.14,15
During PV isolation, most operators use the double transseptal
(DT) approach for simultaneous PV potential monitoring and ablation.
We have previously compared unilateral groin (UG) puncture-
single transseptal (ST) ablation with the conventional bilateral groin
(BG) puncture-double transseptal (DT) ablation in a prospective ran-
domized trial.16 No differences in clinical outcome and complications
were found between the two groups. However, patient's discomfort
about hemostasis was reduced in the UG-ST group than the BG-DT
group. The number of patients in our previous prospective study was
relatively small. Therefore, in the present study, we sought to assess
the effectiveness and safety of ST ablation compared to those of DT
ablation in patients with AF in real-world clinical practice.
2 | METHODS
2.1 | Study population
The study protocol adhered to the Declaration of Helsinki and was
approved by the Institutional Review Board of Yonsei University
Health System. All patients provided written informed consent for
inclusion in the Yonsei AF Ablation Cohort Database (registered at
clinicaltrials.gov as NCT02138695). Among the 1765 consecutive
patients in the Yonsei AF ablation cohort from October 2015 to
January 2020, those who underwent de novo radiofrequency catheter
ablation for circumferential PV isolation (CPVI) were included in the
current analysis (Figure 1). The exclusion criteria were as follows:
(1) valvular AF, (2) structural heart disease other than left ventricular
hypertrophy, (3) cryoablation, (4) history of a previous AF ablation or
cardiac surgery, and (5) extra ablation other than PV ablation in the
LA. The remaining 1144 patients (73.8% male, mean age 58.3
± 10.6 years, 75% with paroxysmal AF) were divided into the ST and
DT groups. Choice of ST or DT approach was dependent on operator
preference. If PV isolation could not be achieved in any patient in the
ST group after three-times of touch-up ablations, the patient was
crossed over to the DT group.
2.2 | Electrophysiological mapping and ablation
In the DT group, both the groins were used. A 14-Fr venous sheath
(Fast-Cath™ Trio, St. Jude Medical Inc.) was introduced into the left
femoral vein, and two long transseptal long sheaths (Schwartz left-1,
8-Fr; Abbott Inc.) were introduced into the right femoral vein. In the
ST group, a single groin was used. A 14-Fr venous sheath and a
transseptal long sheath were introduced into the right femoral
vein. Ablation was performed in all patients using three-dimensional
(3D) electroanatomical mapping (NavX; St Jude Medical Inc., Minne-
tonka, MN, USA) merged with 3D spiral computed tomography (CT).
Systemic anticoagulation was performed with intravenous heparin
to maintain an activated clotting time of 350–400 s during the
procedure.
For PV ablation, continuous circumferential lesions were created
at the level of the LA antrum, encircling the right and left PVs under
the guidance of the NavX system using an open-irrigated, 3.5 mm-tip
deflectable catheter at 30–35 W and 45C (Coolflex [St. Jude Medical
Inc.]). CPVI was performed in all patients. The endpoints of CPVI and
cavotricuspid isthmus (CTI) block were defined on the basis of bidirec-
tional pacing. The procedure ended when no immediate recurrence of
AF was observed within 10 min after cardioversion with an isoproter-
enol infusion (5–10 μg/min). Non-PV foci under an isoproterenol infu-
sion were also ablated.17
F IGURE 1 Flow diagram of the study
population. DT, double trans-septal; LA,
left atrial; PV, pulmonary vein; ST, single
trans-septal
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2.3 | Postablation follow-up
Patients without antiarrhythmic medications were discharged after
the procedure unless early recurrence of AF/atrial tachycardia (AT) or
symptomatic frequent atrial premature beats were evident. The
patients regularly visited the outpatient clinic at 1, 3, 6, and
12 months after catheter ablation and every 6 months thereafter or
whenever symptoms occurred. All patients underwent electrocardiog-
raphy (ECG) at each visit and 24 h Holter recordings at 3 and 6 months
after catheter ablation and every 6 months thereafter according to
the guideline.18 Holter monitoring or event monitor recordings were
obtained when the patients reported symptoms of palpitation sugges-
tive of arrhythmia recurrence. AF recurrence was defined as any epi-
sode of AF or AT lasting for at least 30 s. Any ECG documentation of
an AF recurrence within a 3-month blanking period was diagnosed as
an early recurrence, and an AF recurrence >3 months after the
procedure was diagnosed as a clinical recurrence.
2.4 | Statistical analysis
For the comparison of baseline variables, continuous variables were
analyzed using Student's ttest or analysis of variance, as appropriate.
Categorical variables were analyzed using Pearson's chi-square test.
The AF recurrence-free survival over time was compared between the
ST and DT groups using Kaplan–Meier analysis. Propensity score
matching was performed to adjust for some variables in the two
groups. Statistical analysis was performed using SPSS for Windows
(version 25; IBM Corp., Armonk, NY, USA) and R statistical software.
A p-value of <.05 was considered statistically significant.
3 | RESULTS
3.1 | Baseline and procedure-related
characteristics
Among 1144 patients undergoing AF ablation with PV isolation,
450 patients underwent ST ablation and 694 patients underwent DT
ablation. A total of 844 (73.8%) patients were male and the mean age
of the patients was 58.3 ± 10.6 years (Table 1). The mean age was
higher and the proportion of men was lower in the ST group than in
the DT group. No significant differences were observed in com-
orbidities and echocardiographic parameters between the groups. The
total procedure time, ablation time, and fluoroscopy time were longer
in the ST group than in the DT group (Table 2). The mean hospital
F IGURE 2 Kaplan–Meier curve for AF recurrence-free survival before propensity score matching (A), AF recurrence-free survival off AAD
before propensity score matching (B), AF recurrence-free survival after propensity score matching (C) and AF recurrence-free survival off AAD
after propensity score matching (D). ST, single trans-septal; DT, double trans-septal; AAD, anti-arrhythmic drug
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stays after radiofrequency catheter ablation (RFCA) was 1.3 ± 1.1 days
which was longer in DT group than ST group (p = .001 before propen-
sity score matching and p = .004 after propensity score matching).
The rate of procedure-related complications was 3.7% (42 of
1144 patients). Most of the complications were not significantly dif-
ferent between the groups, including femoral puncture site-related
complications. PV stenosis occurred in three patients, and one of
them was performed balloon angioplasty because of significant steno-
sis. Although PV stenosis was more common in the ST group than in
the DT group, statistical significance could not be estimated because
of the small incidence. Stroke occurred in three patients; all patients
had undergone DT ablation. One of them was transient ischemic
attack and all patients had no significant sequelae after stroke.
3.2 | Clinical rhythm outcomes
The mean follow-up duration was 17.8 ± 13.8 months (Table 2). Clini-
cal recurrence of AF was observed in 221 (19.3%) of 1144 patients.
Among patients with AF recurrence, 371 (35.5%) used antiarrhythmic
drugs (AADs) before recurrence. Patients in the DT group used AADs
more frequently than those in the ST group before clinical recurrence.
The AF recurrence-free survival rate was not significantly different
between the ST group and the DT group in the Kaplan–Meier analysis
(log-rank p = .190, Figure 2(A)). However, after excluding patients
who used AADs when AF recurred, the AF recurrence free-survival
rate was lower in the DT group than in the ST group (log-rank
p = .026, Figure 2(B)).
Among patients who recurred AF, 77 patients performed
redo-ablation. (Table 3). A total of eight patients (10.4%) observed
4PV isolation when PV potential was checked in redo-RFCA. There
was no significant difference in PV reconnection between ST group
and DT group.
3.3 | Outcomes after propensity score matching
After propensity score matching to balance the baseline characteris-
tics between the two groups, the procedure time, ablation time, and
fluoroscopy time were still significantly longer in the ST group than in
the DT group (Table 2). No significant difference in the rate of compli-
cations (4.4% vs. 3.4%, p = .471) was found between the ST and DT
groups. The Kaplan–Meier analysis of the AF-free survival rate also
showed no significant difference between the two groups after pro-
pensity score matching (log-rank p = .600, Figure 2(C)). The AF-free
survival rate was also lower in the DT group than in the ST group after
excluding patients with AAD use in propensity matching (log-rank
p = .047, Figure 2(D)).
4 | DISCUSSION
4.1 | Major findings
Our study divided patients undergoing AF ablation based on the
approach used (ST and DT) to determine the feasibility and safety of
the ST approach. Although the procedure time was increased in the
ST group, the incidence of complications was not significantly differ-
ent between the ST and DT groups. The AF-free survival rates in the
Kaplan–Meier curve were not significantly different between the two
groups. After excluding patients who used AADs when AF recurred,
the AF-free survival rates without AAD use were lower in the DT
group than in the ST group before and after propensity score
matching.
4.2 | Feasibility of the ST approach
ST or DT puncture was used for ablation of AF. Haissaguerre et al
was initially introduced technique using ST puncture and double
transseptal catheterization.7,19 A previous retrospective study15 and
other report20 have showed that ST puncture is safe and could be
used as an alternative to reduce the complications of performing a
second transseptal puncture, such as pericardial tamponade, coronary
artery spasm by mechanical irritation,21 and air embolism.22 However,
ST puncture and double transseptal catheterization sometimes causes
the problem of catheter manipulation.10 Single transseptal catheteri-
zation used in our study resolved the problem of catheter manipula-
tion. The rate of complications in our study was not significantly
different between the two groups. Although we could not conclude
TABLE 3 Redo-ablation
characteristics
Overall (n = 77) ST group (n = 28) DT group (n = 49) p-value
PV reconnection, n (%) .646
4PV isolation 8 (10.4) 4 (14.3) 4 (8.2)
PV reconnection 69 (89.6) 24 (85.7) 45 (91.8)
1 reconnection 14 (18.2) 5 (17.9) 9 (18.4)
2 reconnection 19 (24.7) 6 (21.4) 13 (26.5)
3 reconnection 14 (18.2) 5 (17.9) 9 (18.4)
4 reconnection 22 (28.6) 8 (28.6) 14 (28.6)
Note: Variables are presented as count (percentage).
Abbreviations: DT, double transseptal; PV, pulmonary vein; ST, single transseptal.
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that ST puncture is safer than DT puncture, we could propose that ST
puncture is as safe as DT puncture.
No significant difference was observed between the ST and DT
groups in terms of AF recurrence before and after propensity score
matching. The use of AADs after ablation might affect the AF recur-
rence. After removing the effect of AADs by excluding patients who
used AADs when AF recurred, the risk of AF recurrence was higher in
the DT group than in the ST group. The operators might have been
more careful and took more time to complete CPVI in the ST group
because they could not see the remnant PV potentials spontaneously
to confirm PV isolation, which could have affected the difference in
the risk of AF recurrence between the two groups.
The procedure time and ablation time were higher in the ST
group than in the DT group. The time to exchange the ablation cath-
eter to a mapping catheter might have affected the procedure time
extension in the ST group. ST group performed more CTI ablation
than DT group (98.9% versus 65.9%). It could have impacted the
procedure and fluoroscopy times. As the ST approach was used at
our center from 2015, it took time for achieving the learning curve,
whereas the DT approach has been a routine common approach in
AF ablation.
4.3 | Reduction of postprocedural discomfort after
the ST approach
AF ablation is a complex procedure that requires multiple catheter
positioning and a relatively long procedure time, and continuous
intra- and peri-procedural anticoagulation. The advantage of ST
puncture is that it uses a single groin, which could reduce the time of
hemostasis. A previous report compared the safety and feasibility of
UG-ST ablation with those of BG-DT ablation in patients with parox-
ysmal AF.16 A survey regarding patient discomfort showed that
UG-ST reduced the discomfort with respect to postprocedural
hemostasis compared with BG-DT. When both groins are used,
patients usually experience discomfort with back and leg pain during
postprocedural hemostasis because of immobility for at least 6 h
because of the possibility of bleeding. In patients in the ST group, a
single groin was used during the procedure, allowing them to move
the other leg immediately after the procedure, thus reducing the
discomfort during hemostasis.
Hospital stay after RFCA was significantly reduced in ST group
compared to DT group. Reducing patient's discomfort during
hemostasis might be helpful to reduce hospital stay after RFCA.
4.4 | Potential complications of the ST approach
In the ST approach, the risk of stroke might increase because cathe-
ters are exchanged several times during the procedure. Therefore, we
always irrigated the sheath with saline before catheter exchange to
remove clots and air. However, in the current analysis, no cases of
stroke occurred in the ST group and three cases of stroke occurred in
the DT group. In the DT group, the operator could monitor the PV sig-
nals simultaneously during ablation. Therefore, a concern regarding an
increased risk of AF recurrence may exist in the ST group because of
the higher possibility of missing the gap along the PV antral lesions.
However, our results showed no difference in the rate of AF recur-
rence between the two groups. Also, our results showed no difference
in the number of PV reconnection when we performed redo-RFCA.
Additionally, the rates of AF recurrence were slightly lower in the ST
group than in the DT group after excluding patients using AADs.
However, it is difficult to conclude that the ST approach is more
effective than the DT approach in the current setting, and further
studies would be needed to clarify this issue.
4.5 | Limitations
Our study has several limitations. First, this was an observational
study using a single-center prospective registry that included a highly
selected group of patients referred for AF catheter ablation. The
choice of the ablation strategy depended on the operators' discretion
and experience. Also, selecting the ST or DT approach was decided by
operator preference and it could result in selection bias. To compen-
sate for this limitation, we performed propensity score matching to
adjust the baseline clinical characteristics of the two groups. Second,
there was a significant difference in the percentage of AAD use
between the two groups. Physicians tend to prescribe AADs to
patients who are more likely to develop AF recurrence, such as
patients with more premature atrial contractions. Therefore, this could
have affected the AF-free survival rate after the catheter ablation.
Third, since our study was not randomized, the operator variable
could affect the procedure and the outcome of the study. Fourth,
unlike our previous report, the present study had no objective indica-
tor to prove the reduction of discomfort because of the retrospective
design.
5 | CONCLUSION
The ST approach is as safe as the DT approach and has the advantage
of reducing patient discomfort with respect to hemostasis. Although
the ST approach increases the procedure time compared to the DT
approach owing to the need for more frequent catheter exchanges,
the ST approach is a feasible and safe strategy for AF ablation in terms
of rhythm outcomes and risk of complications.
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